- Home
- FHI vs ACLX Comparison
FHI vs ACLX Comparison
Compare FHI & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FHI | ACLX |
|---|---|---|
| Founded | 1955 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.2B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | FHI | ACLX |
|---|---|---|
| Price | $50.96 | $70.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $49.00 | ★ $115.50 |
| AVG Volume (30 Days) | 517.1K | ★ 1.4M |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ 50.93 | N/A |
| EPS | ★ 4.77 | N/A |
| Revenue | ★ $1,742,513,000.00 | $35,898,000.00 |
| Revenue This Year | $10.23 | N/A |
| Revenue Next Year | $6.95 | $302.49 |
| P/E Ratio | $10.51 | ★ N/A |
| Revenue Growth | ★ 8.98 | N/A |
| 52 Week Low | $35.05 | $47.86 |
| 52 Week High | $54.42 | $94.07 |
Technical Indicators
Market Signals| Indicator | FHI | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 38.06 |
| Support Level | $50.01 | $66.00 |
| Resistance Level | $51.42 | $79.75 |
| Average True Range (ATR) | 0.93 | 5.87 |
| MACD | 0.24 | -0.90 |
| Stochastic Oscillator | 87.20 | 18.10 |
Price Performance
Historical ComparisonAbout FHI Federated Hermes Inc.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $843.7 billion in managed assets at the end of June 2025, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (2%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 52% of Federated's revenue this year, compared with 29%, 11%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.